Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up
Michael Wang(St. Joseph Health System), Kristie A. Blum(Emory University), Michelle Stevens-Brogan(Pharmacyclics (United States)), Jesse McGreivy(Pharmacyclics (United States)), Lori Kunkel(Pharmacyclics (United States)), Peter Martin(Northwestern University), Simon Rule(AstraZeneca (United Kingdom)), Ranjana H. Advani(Stanford Medicine), Brad S. Kahl(UW Health University Hospital), Jorge Romaguera(The University of Texas MD Anderson Cancer Center), André Goy(Hackensack University Medical Center), Rebecca Auer(St Bartholomew's Hospital), Wojciech Jurczak(Jagiellonian University), Fong Clow(Pharmacyclics (United States))
Cited by 26
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k